Journal of Clinical Oncology, Vol 10, 1943-1948, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients

BU Mueller, J Skelton, DP Callender, D Marshall, J Gress, D Longo, J Norton, M Rubin, D Venzon and PA Pizzo
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

PURPOSE: To compare the frequency of infectious episodes or other problems occurring with an externalized catheter (Hickman) versus a subcutaneously implanted device (Port-a-Cath, Pharmacia, Piscataway, NJ) in cancer patients, we performed a prospective, randomized study in 100 cancer patients (age range, 5 to 74 years). PATIENTS AND METHODS: Patients who were chemotherapy candidates and required an indwelling catheter were monitored prospectively and evaluated during the 180 days after the insertion of the catheter and again at time of study closure. The frequency of catheter use, reason for access, and any problems that might have been related to catheter use were noted. All data were collected prospectively and included the patient's age, sex, underlying malignancy, temperature, and leukocyte and absolute granulocyte counts at the time of catheter insertion and when complications occurred. The time to and reason for removal of the catheter, as well as any intercurrent infectious or mechanical problems, were also determined. RESULTS: Most of the infections that occurred were caused by gram- positive organisms, especially staphylococci or streptococci. A total of 22 complications (11 in each group) resulted in removal of the central line. Only one infection in the Hickman catheter group and four in the Port-a-Cath group led to removal of the central line. All other infectious episodes were successfully treated without removal of the catheters. The mean device life was 230 days for the Hickman catheter and 318 days for the Port-a-Cath (not significant). CONCLUSION: There were no differences between the two study groups regarding incidence of documented infections or mechanical or thrombotic complications.

This article has been cited by other articles:

				M. Gallieni, M. Pittiruti, and R. Biffi Vascular Access in Oncology Patients CA Cancer J Clin, November 1, 2008; 58(6): 323 - 346. [Abstract] [Full Text] [PDF]

				C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann. Onc., May 1, 2008; 19(5): 920 - 926. [Abstract] [Full Text] [PDF]

				N. Fernandez-Hidalgo, B. Almirante, R. Calleja, I. Ruiz, A. M. Planes, D. Rodriguez, C. Pigrau, and A. Pahissa Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study J. Antimicrob. Chemother., June 1, 2006; 57(6): 1172 - 1180. [Abstract] [Full Text] [PDF]

				C.-H. Kohne and G. Folprecht On prejudice and facts and choices Ann. Onc., February 1, 2006; 17(2): 185 - 187. [Full Text] [PDF]

				M. Karthaus, A. Kretzschmar, H. Kroning, M. Biakhov, D. Irwin, N. Marschner, C. Slabber, G. Fountzilas, A. Garin, N. G. F. Abecasis, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Ann. Onc., February 1, 2006; 17(2): 289 - 296. [Abstract] [Full Text] [PDF]

				T. W. McLean, C. J. Fisher, B. M. Snively, and A. R. Chauvenet Central Venous Lines in Children With Lesser Risk Acute Lymphoblastic Leukemia: Optimal Type and Timing of Placement J. Clin. Oncol., May 1, 2005; 23(13): 3024 - 3029. [Abstract] [Full Text] [PDF]

				R. Biffi, S. Pozzi, A. Agazzi, U. Pace, A. Floridi, S. Cenciarelli, V. Peveri, A. Cocquio, B. Andreoni, and G. Martinelli Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients Ann. Onc., February 1, 2004; 15(2): 296 - 300. [Abstract] [Full Text] [PDF]

				M. Verso and G. Agnelli Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients J. Clin. Oncol., October 1, 2003; 21(19): 3665 - 3675. [Abstract] [Full Text] [PDF]

				C. P. W. Klerk, S. M. Smorenburg, and H. R. Buller Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review Arch Intern Med, September 8, 2003; 163(16): 1913 - 1921. [Abstract] [Full Text] [PDF]

				C. Male, P. Chait, M. Andrew, K. Hanna, J. Julian, and L. Mitchell Central venous line-related thrombosis in children: association with central venous line location and insertion technique Blood, June 1, 2003; 101(11): 4273 - 4278. [Abstract] [Full Text] [PDF]

				G. Basaglia, E. Carretto, D. Barbarini, L. Moras, S. Scalone, P. Marone, and P. De Paoli Catheter-Related Bacteremia Due to Kocuria kristinae in a Patient with Ovarian Cancer J. Clin. Microbiol., January 1, 2002; 40(1): 311 - 313. [Abstract] [Full Text] [PDF]

				Y. Haimi-Cohen, N. Husain, J. Meenan, G. Karayalcin, M. Lehrer, and L. G. Rubin Vancomycin and Ceftazidime Bioactivities Persist for at Least 2 Weeks in the Lumen in Ports: Simplifying Treatment of Port-Associated Bloodstream Infections by Using the Antibiotic Lock Technique Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1565 - 1567. [Abstract] [Full Text]

				D. Kuizon, S. M. Gordon, and B. L. Dolmatch Single-Lumen Subcutaneous Ports Inserted by Interventional Radiologists in Patients Undergoing Chemotherapy: Incidence of Infection and Outcome of Attempted Catheter Salvage Arch Intern Med, February 12, 2001; 161(3): 406 - 410. [Abstract] [Full Text] [PDF]

				P. Brazzola, R. Zbinden, C. Rudin, U. B. Schaad, and U. Heininger Brevibacterium casei Sepsis in an 18-Year-Old Female with AIDS J. Clin. Microbiol., September 1, 2000; 38(9): 3513 - 3514. [Abstract] [Full Text]

				E. J. Bow, M. G. Kilpatrick, and J. J. Clinch Totally Implantable Venous Access Ports Systems for Patients Receiving Chemotherapy for Solid Tissue Malignancies: A Randomized Controlled Clinical Trial Examining the Safety, Efficacy, Costs, and Impact on Quality of Life J. Clin. Oncol., April 1, 1999; 17(4): 1267 - 1267. [Abstract] [Full Text] [PDF]

				D A Tweddle, K P Windebank, A M Barrett, D C Leese, and R Gowing Central venous catheter use in UKCCSG oncology centres Arch. Dis. Child., July 1, 1997; 77(1): 58 - 59. [Abstract] [Full Text]

				P. A. Pizzo Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia N. Engl. J. Med., May 6, 1993; 328(18): 1323 - 1332. [Full Text]